Johnson Investment Counsel Inc. Has $2.44 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Johnson Investment Counsel Inc. reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,790 shares of the specialty pharmaceutical company’s stock after selling 1,100 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Jazz Pharmaceuticals were worth $2,437,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of JAZZ. Crossmark Global Holdings Inc. increased its holdings in shares of Jazz Pharmaceuticals by 23.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company’s stock worth $567,000 after purchasing an additional 970 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $625,000. Venturi Wealth Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the period. American Assets Inc. bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $557,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 23.3% during the 3rd quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock worth $28,220,000 after purchasing an additional 47,807 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JAZZ has been the subject of a number of analyst reports. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $190.53.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. This represents a 13.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,333 shares of company stock valued at $3,690,226 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $136.86 on Wednesday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The company’s 50 day moving average price is $128.70 and its two-hundred day moving average price is $120.40. The company has a market capitalization of $8.31 billion, a P/E ratio of 19.28, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.